MIROCALS Consortium announces top-line results of European trial at 33rd International MND Symposium
The MIROCALS Trial Consortium - which includes scientists from the University of Sheffield - have today announced the top-line results from the phase 2b trial of a low dose Interleukin-2 (ld IL2) in patients with Motor Neurone Disease.
£12 million to accelerate scientific discoveries into new medical treatments
The National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (BRC) has received a £12 million funding boost.
Breaks in what was historically thought to be ‘junk’ DNA give insight into neurological disease
‘Junk’ DNA could unlock new treatments for neurological disorders as scientists discover how its breaks and repairs affect our protection against neurological disease.
Promising MND drug helps slow disease progression and benefits patients physically
Scientists believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care, after the results of a Phase 3 clinical trial showed significant physical benefits for patients after 12 months.